Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company will engage in a fireside chat scheduled for March 11, 2025, at 8:00 AM ET in Miami Beach, Florida.
Investors and interested parties can access a live webcast of the presentation through the events page in the Investor Relations section of Compugen's website (www.cgen.com). A replay option will be made available after the live event concludes.
Compugen (NASDAQ: CGEN), una compagnia di immunoterapia oncologica in fase clinica specializzata nella scoperta di target computazionali, ha annunciato la sua prossima partecipazione alla Global Healthcare Conference di Leerink Partners. L'azienda parteciperà a una chiacchierata informale programmata per l'11 marzo 2025, alle 8:00 AM ET a Miami Beach, Florida.
Gli investitori e le parti interessate possono accedere a una diretta streaming della presentazione attraverso la pagina eventi nella sezione Relazioni con gli Investitori del sito web di Compugen (www.cgen.com). Sarà disponibile un'opzione di replay dopo la conclusione dell'evento dal vivo.
Compugen (NASDAQ: CGEN), una empresa de inmunoterapia oncológica en etapa clínica especializada en el descubrimiento de objetivos computacionales, ha anunciado su próxima participación en la Conferencia Global de Salud de Leerink Partners. La compañía participará en una charla informal programada para el 11 de marzo de 2025, a las 8:00 AM ET en Miami Beach, Florida.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la página de eventos en la sección de Relaciones con Inversores del sitio web de Compugen (www.cgen.com). Se ofrecerá una opción de repetición después de que concluya el evento en vivo.
Compugen (NASDAQ: CGEN), 임상 단계의 암 면역 치료 회사로, 계산적 표적 발견에 전문화되어 있으며, Leerink Partners 글로벌 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 이 회사는 2025년 3월 11일 오전 8시 ET에 플로리다 마이애미 비치에서 예정된 파이어사이드 챗에 참여할 것입니다.
투자자 및 관심 있는 분들은 Compugen 웹사이트의 투자자 관계 섹션의 이벤트 페이지를 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다 (www.cgen.com). 라이브 이벤트가 종료된 후에는 재생 옵션이 제공될 것입니다.
Compugen (NASDAQ: CGEN), une entreprise d'immunothérapie contre le cancer en phase clinique spécialisée dans la découverte de cibles computationnelles, a annoncé sa prochaine participation à la Conférence Mondiale sur la Santé de Leerink Partners. L'entreprise participera à une discussion informelle prévue pour le 11 mars 2025 à 8h00 ET à Miami Beach, en Floride.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la page des événements dans la section Relations Investisseurs du site web de Compugen (www.cgen.com). Une option de rediffusion sera disponible après la fin de l'événement en direct.
Compugen (NASDAQ: CGEN), ein klinisches Unternehmen für Krebsimmuntherapie, das sich auf die rechnergestützte Zielentdeckung spezialisiert hat, hat seine bevorstehende Teilnahme an der Global Healthcare Conference von Leerink Partners angekündigt. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der für den 11. März 2025 um 8:00 Uhr ET in Miami Beach, Florida, geplant ist.
Investoren und Interessierte können über die Veranstaltungsseite im Bereich Investor Relations der Compugen-Website (www.cgen.com) auf einen Live-Stream der Präsentation zugreifen. Nach dem Ende der Live-Veranstaltung wird eine Wiederholungsoption zur Verfügung stehen.
- None.
- None.
HOLON,
A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-a-fireside-chat-at-the-2025-leerink-partners-global-healthcare-conference-302389891.html
SOURCE Compugen Ltd.
FAQ
When is Compugen's (CGEN) presentation at the 2025 Leerink Partners Healthcare Conference?
How can investors watch Compugen's (CGEN) Leerink Partners Conference presentation?
What type of presentation will Compugen (CGEN) deliver at the 2025 Leerink Conference?
Where will the 2025 Leerink Partners Global Healthcare Conference featuring Compugen (CGEN) be held?
